Evidence map›Paper›PMID 35389604›Full record

ArticleArchivos de cardiologia de Mexico2022

[Cardiovascular complications associated with acromegaly. A state-of-the-art].

Marcio Concepción-Zavaleta, Juan Muñoz-Moreno, María Quispe-Flores, Luciana Rafael-Robles, Carlos Lobato-Jeri, Anthony Ramos-Yataco, Luis Concepción-Urteaga, José Paz-Ibarra

Open access · hybridAbstract readEnglish Abstract
In one paragraph

Article in Archivos de cardiologia de Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 3 countries.

Marcio Concepción-ZavaletaServicio de Endocrinología, Clínica Stella Maris, Lima, Perú.
Juan Muñoz-MorenoServicio de Cardiología, Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú.
María Quispe-FloresServicio de Endocrinología, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú.
Luciana Rafael-RoblesServicio de Endocrinología, Hospital Nacional 2 de Mayo, Lima, Perú.
Carlos Lobato-JeriServicio de Cardiología, Instituto Nacional del Corazón, Lima, Perú.
Anthony Ramos-YatacoServicio de Medicina, Hospital Ricardo Cruzado Rivarola, Nasca, Lima, Perú.
Luis Concepción-UrteagaFacultad de Medicina, Universidad Nacional deTrujillo, Trujillo, Lima, Perú.
José Paz-Ibarra
Fondazione Stella Maris · ITHospital Base Guillermo Almenara Irigoyen · PEHospital Nacional Cayetano Heredia · PEHospital Nacional Dos de Mayo · PEInstituto Nacional de Salud del Niño · PENational University of San Marcos · PENational University of Trujillo · PERicardo (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acromegaly is a rare disease, mainly caused by a pituitary tumor secreting growth hormone. It is characterized by slow progression and is associated with a multisystemic involvement, being the cardiovascular system, one of the most involved, even reaching, more than 10 years ago, to represent the main cause of death. Cardiovascular complications develop as a result of elevated blood concentrations of growth hormone and insulin-like growth factor 1, which exert direct and indirect effects on the endothelium, large vessels, kidney and cardiomyocytes; causing arterial hypertension, valve disease, cardiac arrhythmia and a specific heart disease called acromegalic cardiomyopathy. After the literature overview related to the pathophysiology, clinical manifestations, diagnosis and treatment of cardiovascular involvement, we found that from a cardiovascular point of view, patients with acromegaly can range from an asymptomatic state to severe cardiac dysfunction, being the biochemical markers and imaging studies diagnostic tools that allow assessment the degree of cardiovascular disease in order to provide individualized treatment. The normalization of growth hormone and insulin-like growth factor 1 levels improves cardiovascular parameters, and therefore its prognosis.

Indexed as

AcromegalyHeart DiseasesHuman Growth HormoneGrowth HormoneHumansInsulin-Like Growth Factor IGrowth HormoneHuman Growth HormoneInsulin-Like Growth Factor IAcromegalyHeartHeart diseasesHypertension

Identifiers

PMID35389604
PMCPMC9681516
OpenAlexW4225984014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.